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Introduction
According to American Cancer Society projections for
2014, approximately 1.5 million new cancers are expected
to be diagnosed and more than several hundred patients
are expected to die of cancer, with more than 90% of
these cancers being solid tumours (ACS, 2010). Epithelial
cell-derived cancers comprise approximately 80-85% of
all cancers, and include, amongst others, breast, bladder,
lung, pancreatic, thyroid and prostate cancers [1-4].
Presently, breast cancer is the most common cancer
among women worldwide as more than 1 in 4 cancers in
women (about 28%) are of the breast, and thyroid cancer
is the most common epithelial cell-derived malignancy of
the endocrine glands [4,5]. These cancers may exhibit no
signs in its early stages. Further, the aggressive cases are
difficult to detect and when undetected, prognosis dete-
riorates rapidly.
Neutralization antibodies targeted to genes associated
with cancer is a good strategy to detect cancer at early
stages among many treatment approaches because of its
high specificity and affinity. KalGene is developing a
multi-protein assay to identify aggressive epithelial can-
cers, including breast, colon, and prostate, thyroid cancers.
We have successfully developed several monoclonal anti-
bodies against important biomarkers. Our monoclonal
antibodies have shown excellent affinity and specific reac-
tivity to the recombinant protein and cell lysates.
Purified monoclonal antibodies were tested on tissue
microarrays (TMA). Tissue microarray technology
allows a massive acceleration of studies correlating
molecular in situ bindings with clinico-pathological
information. In this method, minute tissue cylinders
(diameter 0.6 mm) are removed from hundreds of dif-
ferent primary tumour blocks and subsequently brought
into one empty ‘recipient’ paraffin block. Sections from
TMA blocks can be used for all different types of in situ
tissue analyses including immunohistochemistry. TMA
sections were de-paraffinized and heat-mediated antigen
retrieval was performed. Non-specific immunoglobulin
binding was blocked with 10% normal horse serum
(NHS) for 30 min at room temperature. The TMA sec-
tions were then incubated with the appropriate diluted
Kalgene monoclonal antibody in NHS. Thereafter, the
slides were incubated with the appropriate secondary
antibody diluted in NHS. Signal from the secondary
antibody can be detected, then visualized.
Results and conclusions
The membranous KAL001 staining was calculated as a
weighted average, based on results from three core sam-
ples per tumour. KAL001 expression levels were posi-
tively associated with well (versus poorly) differentiated
tumours (n = 18; p = 0.05), low preoperative serum carci-
noembryonic antigen (n = 76; p = 0.0002), and 5 year
survival (n = 128; p = 0.01). The presence of perineural
invasion and macroperforation were associated with
lower KAL001 staining scores, but small sample numbers
precluded statistical analysis of these results. Our study
findings demonstrate that reduced KAL001
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